MedTrace Logo

Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation

NCT01798186 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-08-03

Study results available
· View outcomes & findings →

Summary

This primary aim of this study is to assess the effects of passive (second-hand) inhalation of cannabis smoke on toxicological analysis of "native" oral fluid (saliva), urine and blood specimens. The results of this study will help inform the validity of oral fluid as a biomarker of cannabis exposure and to determine whether, and for how long, passive inhalation of cannabis smoke could result in a positive toxicology result.

Conditions

  • Cannabis Toxicology

Interventions

DRUG

Cannabis

Participants will be exposed to cannabis smoke present in ambient air

Sponsors & Collaborators

  • Substance Abuse and Mental Health Services Administration (SAMHSA)

    collaborator FED

  • RTI International

    collaborator OTHER

  • Johns Hopkins University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798186 on ClinicalTrials.gov